All In Biotech

Drug Trial Radar · NCT00134030

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jun 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,334 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,334

Actual

Start

Nov 14, 2005

Primary completion

Jan 31, 2015

Study completion Sep 30, 2022

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); University College, London; Medical Research Council
First posted
Aug 24, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial is studying combination chemotherapy followed by surgery and two different combination chemotherapy regimens with or without PEG-interferon alfa-2b to compare how well they work in treating patients with osteosarcoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Biological therapies, such as PEG-interferon alfa-2b, may interfere with the growth of tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so it can be removed. Giving combination chemotherapy together with PEG-interferon alfa-2b after surgery may kill any remaining tumor cells. It is not yet known whether giving combination therapy together with PEG-interferon alfa-2b is more effective than two different combination chemotherapy regimens alone after surgery in treating osteosarcoma.

Conditions

  • Localized Osteosarcoma
  • Metastatic Osteosarcoma

Interventions

  • CisplatinDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • EtoposideDrug

    Given IV

  • IfosfamideDrug

    Given IV

  • MethotrexateDrug

    Given IV

  • Peginterferon Alfa-2bBiological

    Given subcutaneously

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • Therapeutic Conventional SurgeryProcedure

    Undergo amputation or limb salvage surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS)Time frame: From date of randomization to date of the event.

Locations

218 sites in 6 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Mattel Children's Hospital UCLA

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • Children's Hospital and Research Center at Oakland

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Medical Center-Mount Zion

    San Francisco, California

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Harbor-University of California at Los Angeles Medical Center

    Torrance, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Connecticut

    Farmington, Connecticut

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Lee Memorial Health System

    Fort Myers, Florida

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • University of Florida Health Science Center - Gainesville

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

Showing 40 of 218 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.